Drug Watch

VP-102 could be the first FDA-approved treatment for molluscum contagiosum.

Nivolumab for completely resected stage IIB or IIC melanoma is also validated by the European Medicines Agency.

Biosimilars have been a trending topic in 2023 with 8 adalimumab biosimilars expected to hit the market this year.

Adolescents and adults with seborrheic dermatitis may have a new topical treatment soon.

The expanded approval is based on data from a recent phase 3 clinical trial.

Chronic hand eczema can have a significant negative impact on quality of life.

Newly released safety and efficacy data on Novartis’ secukinumab for hidradenitis suppurativa is published in The Lancet.

Christopher Bunick, MD, PhD, and Raj Chovatiya, MD, PhD, discuss the benefits of adalimumab-atto and the future of additional biosimilars in 2023.

Preventing generalized pustular psoriasis may be possible based on recent data.

Breakthroughs and approvals we can expect in the coming year.

Potential FDA approval is expected in the first quarter of 2024.

Arcutis Biotherapeutics' indication expansion is based on data from MUSE studies.

Dermavant announced positive results from its pediatric maximal usage study.

BLA submission is based on phase 3 trial results evaluating the safety and efficacy of lebrikizumab.

Brexogen Inc.’s exosome therapy is the first entry of a clinical trial of exosome treatment for atopic dermatitis.

Alphyn Biologics’ study of AB-101a also evaluates patients who suffer from bacterial infections associated with atopic dermatitis.

Arcutis Biotherapeutics announced positive results from the ARRECTOR phase 3 trial.

Boehringer Ingelheim’s first treatment option for adults will help manage burdensome flares.

INTEGUMENT-1 and 2 trial data for atopic dermatitis are expected at the end of 2022.

MediWound’s new burn care therapy alleviates risks associated with surgical debridement.

Allergan Aesthetics announced the US Food and Drug Administration has approved the hyaluronic acid filler for jawline definition improvement.

Arcutis Biotherapeutics’ roflumilast cream will provide relief to patients aged 12 years or older diagnosed with plaque psoriasis.

Approval of a novel oral JAK inhibitor specifically indicated for this challenging condition fills a long unmet need.

An early-stage clinical trial will evaluate an investigational vaccine to prevent Nipah virus infection.

The groundbreaking approval of sirolimus topical gel brings relief to patients with facial angiofibroma related to tuberous sclerosis complex with the first FDA-approved topical treatment.

Cynthia J. Trickett, PA-C, MPAS, discusses the personal and clinical effects of atopic dermatitis in adult and pediatric patients at the Maui Derm NP+PA 2022 Summer Conference in Colorado Springs, Colorado.

Verrica is complying with the FDA through 3 Complete Response Letters to achieve the first FDA-approved treatment of molluscum contagiosum.

Complex diseases can be difficult to manage for optimal outcomes. Monitoring programs of therapies can help with that management

In this week’s Pointers with Dr Portela, the 208SkinDoc talks the newest approval of baricitinib (Olumiant; Eli Lilly and Company) for the treatment of alopecia areata.

Click here to answer this week's poll.